Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Lupuzor could treat a number of diseases, says creator

Sylvaine Muller, creator of ImmuPharma PLC’s (LON:IMM) lead drug candidate Lupuzor, tells Proactive Investors the treatment is “unique” in its treatment for auto-immune disease lupus, as it only targets only the autoimmune system, and not the immune system.

But, she adds, “we think that we can open up the indications in which the peptide [molecule] could be effective”.

“We have already started some experiments,” Mulller says, which will target a range of diseases including inflammatory, chronic, those related to autoimmunity and those that aren’t - like asthma.

“We have first indication that are extremely promising also in these indications,” she adds.

 
Meet Rainbow Rare Earths Limited, Eurasia Mining plc, Mariana Resources Ltd., Anglo Asian Mining Plc and Hannan Metals Ltd at our event, London, 09 May 2017. Register here »
View full IMM profile

ImmuPharma PLC Timeline

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use